Innovative technology performs automatic segmentation and lesion detection in prostate MRI scans to assist in PI-RADS scoring for prostate cancer management TEL AVIV, Israel & SAN JOSE, ...

Thanks to early detection and aggressive treatment for prostate cancer, 97 percent of all men diagnosed with the disease will survive at least 5 years and nearly 80 percent will survive at least a ...

Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Recent ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Details on ...

Researcher in lab An AI tool outperformed NCCN guidelines for predicting biochemical failure, distant metastasis, prostate cancer-specific survival, and overall survival. An artificial intelligence ...

Digital rectal examination (DRE) is neither helpful nor useful as a solitary prostate cancer screening tool in middle-aged men, say investigators reporting the PROBASE study. The study compared ...

The diagnostic imaging provider RadNet has secured two software clearances from the FDA to help radiologists spot cases of breast and prostate cancer. The programs were developed by its artificial ...

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Dr. Daniel P. Petrylak about PSMA, what it is and how it is advancing the prostate cancer landscape. Kristie ...

U.S. Senator John Boozman (R-AR) was recognized for his leadership in advancing policiies that prioritize enhanced care and research for prostate cancer.

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...